Literature DB >> 29616133

Mismatch repair single nucleotide polymorphisms and thyroid cancer susceptibility.

Luís S Santos1,2, Susana N Silva1, Octávia M Gil1,3, Teresa C Ferreira4, Edward Limbert4, José Rueff1.   

Abstract

Thyroid cancer (TC) is the most common endocrine malignancy and its incidence continues to rise worldwide. Ionizing radiation exposure is the best established etiological factor. Heritability is high; however, despite valuable contribution from recent genome-wide association studies, the current understanding of genetic susceptibility to TC remains limited. Several studies suggest that altered function or expression of the DNA mismatch repair (MMR) system may contribute to TC pathogenesis. Therefore, the present study aimed to evaluate the potential role of a panel of MMR single nucleotide polymorphisms (SNPs) on the individual susceptibility to well-differentiated TC (DTC). A case-control study was performed involving 106 DTC patients and 212 age- and gender-matched controls, who were all Caucasian Portuguese. Six SNPs present in distinct MMR genes (MLH1 rs1799977, MSH3 rs26279, MSH4 rs5745325, PMS1 rs5742933, MLH3 rs175080 and MSH6 rs1042821) were genotyped through TaqMan® assays and genotype-associated risk estimates were calculated. An increased risk was observed in MSH6 rs1042821 variant homozygotes [adjusted odds ratio (OR)=3.42, 95% CI: 1.04-11.24, P=0.04, under the co-dominant model; adjusted OR=3.84, 95% CI: 1.18-12.44, P=0.03, under the recessive model]. The association was especially evident for the follicular histotype and female sex. The association was also apparent when MSH6 was analysed in combination with other MMR SNPs such as MSH3 rs26279. Interestingly, two other SNP combinations, both containing the MSH6 heterozygous genotype, were associated with a risk reduction, suggesting a protective effect for these genotype combinations. These data support the idea that MMR SNPs such as MSH6 rs1042821, alone or in combination, may contribute to DTC susceptibility. This is coherent with the limited evidence available. Nevertheless, further studies are needed to validate these findings and to establish the usefulness of these SNPs as genetic susceptibility biomarkers for DTC so that, in the near future, cancer prevention policies may be optimized under a personalized medicine perspective.

Entities:  

Keywords:  DNA repair; MSH6; genetic susceptibility; mismatch repair; single nucleotide polymorphism; thyroid cancer

Year:  2018        PMID: 29616133      PMCID: PMC5876466          DOI: 10.3892/ol.2018.8103

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  73 in total

1.  SNPStats: a web tool for the analysis of association studies.

Authors:  Xavier Solé; Elisabet Guinó; Joan Valls; Raquel Iniesta; Víctor Moreno
Journal:  Bioinformatics       Date:  2006-05-23       Impact factor: 6.937

2.  Genome-wide association study on differentiated thyroid cancer.

Authors:  Aleksandra Köhler; Bowang Chen; Federica Gemignani; Rossella Elisei; Cristina Romei; Gisella Figlioli; Monica Cipollini; Alfonso Cristaudo; Franco Bambi; Per Hoffmann; Stefan Herms; Michal Kalemba; Dorota Kula; Shelley Harris; Peter Broderick; Richard Houlston; Susana Pastor; Ricard Marcos; Antonia Velázquez; Barbara Jarzab; Kari Hemminki; Stefano Landi; Asta Försti
Journal:  J Clin Endocrinol Metab       Date:  2013-07-26       Impact factor: 5.958

3.  A genome-wide association study yields five novel thyroid cancer risk loci.

Authors:  Julius Gudmundsson; Gudmar Thorleifsson; Jon K Sigurdsson; Lilja Stefansdottir; Jon G Jonasson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Hrefna Johannsdottir; Gisli H Halldorsson; Simon N Stacey; Hannes Helgason; Patrick Sulem; Leigha Senter; Huiling He; Sandya Liyanarachchi; Matthew D Ringel; Esperanza Aguillo; Angeles Panadero; Enrique Prats; Almudena Garcia-Castaño; Ana De Juan; Fernando Rivera; Li Xu; Lambertus A Kiemeney; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Hoskuldur Kristvinsson; Romana T Netea-Maier; Thorvaldur Jonsson; Jose I Mayordomo; Theo S Plantinga; Hannes Hjartarson; Jon Hrafnkelsson; Erich M Sturgis; Unnur Thorsteinsdottir; Thorunn Rafnar; Albert de la Chapelle; Kari Stefansson
Journal:  Nat Commun       Date:  2017-02-14       Impact factor: 14.919

4.  Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome.

Authors:  Jennifer M Johnson; Jason Chen; Siraj M Ali; Inderpreet K Dardi; Madalina Tuluc; David Cognetti; Barbara Campling; Ashwin R Sama
Journal:  J Gastrointest Cancer       Date:  2018-06

5.  Association studies in thyroid cancer susceptibility: are we on the right track?

Authors:  Iñigo Landa; Mercedes Robledo
Journal:  J Mol Endocrinol       Date:  2011-08-03       Impact factor: 5.098

6.  Polymorphisms in base excision repair genes and thyroid cancer risk.

Authors:  Luís S Santos; Sandra C Branco; Susana N Silva; Ana Paula Azevedo; Octávia M Gil; Isabel Manita; Teresa C Ferreira; Edward Limbert; José Rueff; Jorge F Gaspar
Journal:  Oncol Rep       Date:  2012-08-22       Impact factor: 3.906

7.  Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs.

Authors:  Yoji Kukita; Jiro Okami; Noriko Yoneda-Kato; Ikuko Nakamae; Takeshi Kawabata; Masahiko Higashiyama; Junya Kato; Ken Kodama; Kikuya Kato
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

8.  Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study.

Authors:  João Conde; Susana N Silva; Ana P Azevedo; Valdemar Teixeira; Julieta Esperança Pina; José Rueff; Jorge F Gaspar
Journal:  BMC Cancer       Date:  2009-09-25       Impact factor: 4.430

9.  Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility.

Authors:  Yadav Sapkota; John R Mackey; Raymond Lai; Conrado Franco-Villalobos; Sasha Lupichuk; Paula J Robson; Karen Kopciuk; Carol E Cass; Yutaka Yasui; Sambasivarao Damaraju
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

10.  Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.

Authors:  Yang Yu; Li Dong; Dapeng Li; Shaokun Chuai; Zhigang Wu; Xiangqian Zheng; Yanan Cheng; Lei Han; Jinpu Yu; Ming Gao
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

View more
  5 in total

1.  Complex mutation profiles in mismatch repair and ribonucleotide reductase mutants reveal novel repair substrate specificity of MutS homolog (MSH) complexes.

Authors:  Natalie A Lamb; Jonathan E Bard; Raphael Loll-Krippleber; Grant W Brown; Jennifer A Surtees
Journal:  Genetics       Date:  2022-07-30       Impact factor: 4.402

2.  Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  JNCI Cancer Spectr       Date:  2018-12-10

3.  Micronuclei Formation upon Radioiodine Therapy for Well-Differentiated Thyroid Cancer: The Influence of DNA Repair Genes Variants.

Authors:  Luís S Santos; Octávia M Gil; Susana N Silva; Bruno C Gomes; Teresa C Ferreira; Edward Limbert; José Rueff
Journal:  Genes (Basel)       Date:  2020-09-17       Impact factor: 4.096

Review 4.  DNA Mismatch Repair Gene Variants in Sporadic Solid Cancers.

Authors:  Fabian Caja; Ludmila Vodickova; Jan Kral; Veronika Vymetalkova; Alessio Naccarati; Pavel Vodicka
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

5.  Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.

Authors:  Kshama Aswath; James Welch; Sriram Gubbi; Padmasree Veeraraghavan; Shirisha Avadhanula; Sudheer Kumar Gara; Esra Dikoglu; Maria Merino; Mark Raffeld; Liqiang Xi; Electron Kebebew; Joanna Klubo-Gwiezdzinska
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-13       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.